NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Natures Sunshine Products Inc. NATR
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$480.1M
▲ 5.7% vs FY2024
EPS · FY25
$1.06
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
4.1%
Dividend coverage
1.4×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 480.1M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
4 cents of every revenue dollar became profit this year.
Per share
USD 1.06
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 1.4 times — the rest stayed in the company.
Profitability
—
Return on equity, FY2025
ROE
Operating margin5.2%
Net margin4.1%
Return on assets7.8%
Returned to shareholders
USD 16.3M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 16.3M
Share of profit83.5%
Consecutive raises—
USD 16.3M in buybacks — 84% of the year's profit went back to shareholders.
Growth
+4.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+4.4%
+4.5%
+4.0%
+2.1%
Net income
−3.2%
+3.6%
EPS, diluted
−0.2%
+3.2%
Returned to shareholders
+6.3%
+4.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years−11.1%
Change, 10 years−5.8%
The share count shrank 11% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 261.1M
total assets, end of FY2025
Total assetsUSD 261.1M
CashUSD 93.9M
Current ratio2.28×
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.5
0.5
0.4
0.4
0.4
0.4
0.4
0.4
0.3
0.3
0.3
0.4
0.4
0.4
0.4
0.3
0.3
Operating income $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EBITDA $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
EPS, diluted $
1.06
0.40
0.77
−0.02
1.42
1.07
0.34
−0.04
−0.69
0.11
0.77
0.56
1.07
1.59
1.12
−0.08
0.39
Dividend / sh $
·
·
·
0.00
1.00
0.00
0.00
0.00
0.10
0.40
0.40
1.90
1.90
0.15
·
·
0.05
Payout %
·
·
·
−0
66
0
·
−0
−13
1112
55
359
173
9
·
·
13
ROE %
·
·
·
·
·
·
·
·
·
·
·
9.3
15.9
25.0
22.6
−2.0
10.7
Shares out B
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
65 of 65
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed